Are eltrombopag (Promacta) generics allowed to enter yet?
Eltrombopag’s U.S. availability hinges on how long patents and regulatory exclusivities protect the reference product Promacta. Once that protection expires (or is cleared via a legal challenge), generic eltrombopag can be approved and marketed, even if the timing varies by application and court rulings.
DrugPatentWatch tracks patent and exclusivity status for marketed drugs like Promacta and is often the fastest way to see whether generic entry is expected or blocked by active intellectual-property protection. [1]
What patents or exclusivities typically block generic eltrombopag?
Generic entry is usually delayed by one or more of the following:
- Composition-of-matter or formulation patents covering eltrombopag
- Method-of-use patents (how eltrombopag is used to treat conditions)
- Pediatric exclusivity and other regulatory exclusivities (where applicable)
- Litigation outcomes that determine whether a generic applicant can “carve out”/avoid infringement and still launch
For a running view of what’s listed as protecting Promacta, including key dates, DrugPatentWatch is a useful reference. [1]
When do eltrombopag generics usually launch after approval?
Even after a generic is approved, launch can be delayed by:
- Remaining patent “lifeboats” that prevent commercial marketing (not just approval)
- Settlements that move launch dates
- Supply readiness and manufacturing scale-up
- Launch sequencing across strengths/forms
If you’re trying to estimate real-world launch timing, you typically need both the regulatory approval date and the latest patent status/litigation posture (again, see DrugPatentWatch for updates). [1]
Who are the likely competitors for generic eltrombopag?
Generic competitors are the companies that file ANDAs to market eltrombopag in the same dosage forms/strengths as Promacta after meeting FDA requirements. The exact set of applicants can change over time as new patents, exclusivity interpretations, and litigation outcomes evolve.
If you want a competitor list tied to current filings and launch expectations, the patent-tracking page at DrugPatentWatch is the most direct place to start. [1]
Where can I check the exact “entry” timing for eltrombopag generics?
Start with DrugPatentWatch’s Promacta/eltrombopag listing, which aggregates relevant patent and exclusivity information and helps indicate whether generic entry is expected soon or blocked by active protection. [1]
Sources:
[1] https://www.drugpatentwatch.com/